XNCR Xencor Inc.

-0.11  -0%
Previous Close 44.02
Open 44.03
Price To Book 4.06
Market Cap 2,474,472,832
Shares 56,353,287
Volume 59,319
Short Ratio
Av. Daily Volume 550,868

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data released October 5, 2018. Primary endpoint not met.
Systemic Lupus Erythematosus (SLE)
Phase 3 trial to be initiated - partner required.
IgG4-Related Disease (IgG4-RD)
Phase 1 trial placed on partial clinical hold - February 20, 2019.
Acute Myeloid Leukemia (AML)
Phase 1 initial data due 2H 2019.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 initial data due 2H 2019.
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)
Phase 1 initiation of dosing announced May 6, 2019.
XmAb23104-01 (DUET-3)
Solid tumors
Phase 1 commencement of dosing announced June 3, 2019.
Solid tumors
Phase 1 initial data due 2H 2019.
XmAb20717 (DUET-2)
Solid tumors